Expert review finds Alzheimer’s drugs offer no meaningful benefit

An international review has found that anti‑amyloid drugs developed to treat Alzheimer’s disease provide no clinically meaningful benefit to patients, despite decades of research and global investment.

The findings have intensified debate over the long‑dominant amyloid hypothesis and prompted calls for a broader shift in dementia research.

The Cochrane review analysed 17 clinical trials involving 20,342 participants with mild cognitive impairment or early Alzheimer’s disease. While the drugs successfully removed amyloid beta proteins from the brain, researchers found the impact on memory, thinking and daily functioning was absent or trivial, falling well below accepted thresholds for clinical relevance.

“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” said lead author Dr Francesco Nonino, neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna.

“There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect.”

The review also found that anti‑amyloid drugs likely increase the risk of brain swelling and bleeding, detected on MRI scans. Most cases were asymptomatic, but researchers say the long‑term consequences remain unclear due to inconsistent reporting across trials.

These safety concerns have been central to regulatory decisions. Several international agencies, including Australia’s Pharmaceutical Benefits Advisory Committee, have declined to approve some anti‑amyloid drugs on efficacy grounds, while others, such as the FDA in the United States, have taken a different approach.

Experts anticipate intense debate

Professor Amy Brodtmann, from Monash University’s Cognitive Health Initiative, said the review’s conclusions align with decisions by many regulators but will be “contentious” within the Alzheimer’s research community.

“Their sobering conclusion that successful removal of amyloid does not seem to be associated with clinically meaningful effects will spark intense debate,” she said.

“However, many clinicians will welcome this objective guidance for evidence‑based care.”

She noted that the review included older trials of drugs with weaker amyloid‑clearing effects, which may influence the overall findings. A pooled analysis of the three agents with positive trials — aducanumab, lecanemab and donanemab — would have been informative, she said.

Dr Nikki‑Anne Wilson, a cognitive neuroscientist at the University of NSW (UNSW) and NeuRA, said the findings highlight the complexity of Alzheimer’s disease and the limitations of targeting a single biological pathway.

“The brain is complex and what this review highlights is that a single mechanism is unlikely to offer the magic bullet we seek,” she said.

“This is one reason multi‑domain approaches have shown promise, because they target different mechanisms.”

She said the results should refocus attention on the 14 modifiable dementia risk factors identified by the Lancet Commission, including physical activity, hearing loss, social engagement and cardiovascular health.

“What we have now is robust evidence‑based approaches for supporting brain health across life, which, if broadly implemented, will likely reduce the number of people diagnosed with Alzheimer’s disease in the future.”

‘Sobering verdict’

Professor Bryce Vissel, from UNSW’s Faculty of Medicine, said the review delivers a “sobering verdict” on drugs that have been widely promoted as the first treatments capable of slowing Alzheimer’s disease.

He said the average improvements seen across trials were “very small changes, unlikely to be truly noticeable to most patients or families in daily life”, despite strong plaque‑clearing effects on brain scans.

“The overall signal from more than 20,000 participants is clear: strong plaque removal has not translated into meaningful gains in memory, thinking, daily function or independence,” he said.

He also highlighted the safety concerns, noting that brain swelling occurred in about 119 per 1000 treated patients, compared with 12 per 1000 on placebo.

“These are intensive, expensive treatments that require repeated infusions and repeated MRI monitoring,” he said.

“The longer‑term safety picture remains unsettled.”

The review arrives at a pivotal moment, as ageing populations drive urgent demand for effective treatments. While anti‑amyloid drugs have dominated research pipelines for decades, the findings suggest the field may be entering a new phase.

Professor Vissel said the results should prompt a broader, more individualised approach to Alzheimer’s research.

“No patient can derive benefit from plaque clearance unless it translates into tangible improvements in quality of life,” he said.

“The field now needs a broader approach with a sharp focus on preserving cognition, daily function and independence.”

The review’s senior author, Professor Edo Richard, from Radboud University Medical Centre in the Netherlands, agreed that new directions are needed.

“Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments,” he said.

“Given the absence of correlation between amyloid removal and clinical benefit, we need to explore other pathways.”